AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026
Amgen (AMGN) will present data at ACR Convergence 2026, including Phase 3 results for dazodalibep in Sjögren's disease, showing significant improvements in systemic disease activity and patient-reported dryness. The study met primary and key secondary endpoints. Additional data on UPLIZNA, KRYSTEXXA, and TAVNEOS will also be presented.
How this was made
The 30-second read
Why it matters
The disclosed Phase 3 results provide the first robust efficacy signal for dazodalibep, a first‑in‑class CD40L antagonist, addressing a disease with no approved therapies.
Market read
Positive trial data could lift Amgen's stock and influence sentiment toward rare‑autoimmune therapeutics.
What to watch
Potential safety signals or competitive pipeline advances could temper upside.
Background
Amgen announced multiple abstracts for its autoimmune portfolio at the American College of Rheumatology conference, highlighting new data for dazodalibep, UPLIZNA, KRYSTEXXA, and TAVNEOS.
Ticker impact
Amgen disclosed Phase 3 OASIZ-301 trial results for dazodalibep showing statistically significant improvement in Sjögren's disease activity and dryness.
likely upward pressure as market prices in the favorable trial outcomes
First-time disclosure of statistically significant efficacy in an unmet‑need disease typically drives buying interest.
Market effects
strengthens the rare‑autoimmune therapeutic segment and may lift peers with similar pipelines
U.S. biotech sector could see modest gains
reinforces confidence in late‑stage autoimmune drug development worldwide
Counterpoint
If data does not translate to regulatory approval or commercial uptake, the rally could be short‑lived.
Key entities
- companyAmgen
US‑listed biotech firm (NASDAQ: AMGN) presenting trial data.
- drugDazodalibep
Investigational CD40L antagonist for Sjögren's disease.
